Topic: Narrow Therapeutic Index Drugs

Why Tight NTI Limits Are Not Variance-Scaled Limits

Worked Replicate-Study Analysis for an NTI Drug

Setting Cmax Criteria for Peak-Sensitive NTI Drugs

Selecting Replicate Crossover Designs for NTI Studies

Reaching Joint AUC and Cmax Decisions

Linking Exposure Differences to NTI Clinical Risk

Mixed-Effects Models for NTI Replicate Crossover Studies

Interpreting PK Equivalence With Therapeutic Drug Monitoring

Interpreting Test–Reference Variability Comparisons

Identifying NTI Medicines for Bioequivalence